Video

Dr. Vokes on Cetuximab for Head and Neck Cancer

Dr. Everett Vokes from University of Chicago Medical Center on Cetuximab for Head and Neck Cancer

Everett E. Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, Physician-in-Chief, Chair, Department of Medicine, University of Chicago Medical Center, discusses the use of cetuximab (Erbitux), an epidermal growth factor receptor (EGFR) inhibitor, for advanced head and neck cancer.

Vokes explains that an examination of the clinical data does not provide a clear picture of cetuximab’s efficacy. As a single agent it induces a response in 15-20% of patients, however, given the frequency of EGFR overexpression in head and neck cancer it could be assumed that this number should be higher.

The FDA recently approved cetuximab,in combination with chemotherapy, for advanced head and neck cancer patients. This trial added cetuximab to 5-fluorouracil and either cisplatin or carboplatin. The combination arm of the trial experienced a 2.7-month increase in survival over chemotherapy alone.

Vokes describes this trial as a breakthrough for these patients because it is the first of its kind to demonstrate an increase in survival.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity